Curative Care

curative.org

Curative Care is a leading community resource that provides high quality services to children, adults and senior citizens with disabilities or limiting conditions at community-based sites and natural settings in Milwaukee and surrounding counties. Our proven programs offer a variety of purposeful, goal-oriented activities and opportunities that promote independence and enrich lives. We see people for their abilities and our amazing staff works with them to improve their function and quality of life.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

news image

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

news image

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More

Cell and Gene Therapy

BIOGEN AND GINKGO BIOWORKS COLLABORATE AND LICENSE AGREEMENT TO DEVELOP NOVEL GENE THERAPY MANUFACTURING PLATFORM

Biogen, Ginkgo Bioworks | May 22, 2021

news image

Biogen and Ginkgo Bioworks announced a partnership in gene therapy today. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors by working together. Recombinant AAV-based vectors are extensively used in the development of novel gene therapies with the ability to cure neurological and neuromuscular diseases, as well as other conditions in a variety of therapeutic areas. Manufacturing is now time-consuming and ex...

Read More

Medical

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

news image

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More
news image

Medical

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More
news image

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More
news image

Cell and Gene Therapy

BIOGEN AND GINKGO BIOWORKS COLLABORATE AND LICENSE AGREEMENT TO DEVELOP NOVEL GENE THERAPY MANUFACTURING PLATFORM

Biogen, Ginkgo Bioworks | May 22, 2021

Biogen and Ginkgo Bioworks announced a partnership in gene therapy today. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors by working together. Recombinant AAV-based vectors are extensively used in the development of novel gene therapies with the ability to cure neurological and neuromuscular diseases, as well as other conditions in a variety of therapeutic areas. Manufacturing is now time-consuming and ex...

Read More
news image

Medical

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More